We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MCED Could Be Valuable Supplement to Traditional Cancer Screening Approaches

By LabMedica International staff writers
Posted on 10 Jul 2025

Current cancer screening methods are limited in scope, primarily focusing on a few high-incidence cancer types, such as those detected by mammography, colonoscopy, and low-dose computed tomography (LDCT). More...

These traditional methods often have high false-positive rates and require invasive procedures, leading to poor patient adherence and limited overall effectiveness. Additionally, detecting cancer early—when it is most treatable—remains a challenge. Liquid biopsy-based multi-cancer early detection (MCED) has been identified as a potential breakthrough, offering a non-invasive, multi-cancer diagnostic approach. By analyzing biological markers such as cfDNA, cfRNA, and proteins from blood or body fluids, MCED can detect multiple cancers simultaneously and potentially localize the tissue of origin, offering a promising solution for earlier and more effective cancer detection.

Researchers from the Chinese Academy of Medical Sciences (CACMS, Beijing, China) and collaborators have explored the road for liquid biopsy-based MCED from evidence to implementation in a paper published in Science Bulletin. The technology utilizes liquid biopsy to analyze biomarkers in blood or other body fluids, leveraging AI algorithms to enhance detection accuracy. This approach offers broad population and cancer-type coverage, minimal invasiveness, and high patient compliance. The MCED method works by analyzing cfDNA, cfRNA, and proteins to detect cancer markers, expanding screening to a wider range of cancers. While MCED holds potential, further validation through clinical trials and real-world evidence is needed to establish its clinical efficacy. The MCED method has been evaluated through various clinical trials, and results show significant promise.

The findings indicate that MCED technology offers improved sensitivity and specificity over existing screening techniques, enabling the detection of cancers earlier and with greater accuracy. The technology could also potentially reduce late-stage cancer incidence, leading to better outcomes and lower healthcare costs. However, challenges remain, such as balancing surrogate endpoints with actual public health benefits, improving early detection for cancers with low cfDNA shedding, and minimizing false positives and mislocalization errors. Researchers are working to refine the technology, focusing on clinical validation, cost control, and enhancing evidence generation to support MCED’s future implementation as a complementary tool to existing cancer screening approaches.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.